Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Overview
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Companies Involved in Therapeutics Development
Ahn-Gook Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Daewoong Pharmaceutical Co Ltd
Eisai Co Ltd
Handa Pharmaceuticals LLC
Ilyang Pharmaceutical Co Ltd
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
RaQualia Pharma Inc
Sam-A Pharm Co Ltd
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Drug Profiles
(esomeprazole + sodium bicarbote) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azeloprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceclazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-30065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colesevelam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-14012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-17DT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IYHCR-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-1366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SA-15001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vonoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YY-DXR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Product Development Milestones
Featured News & Press Releases
Oct 08, 2018: Ironwood Pharmaceuticals presents IW-3718 data at the American College of Gastroenterology 2018 Annual Scientific Meeting
Jul 06, 2018: Ministry approves CJ Healthcares Gastro esophageal reflux treatment
Jul 06, 2018: RaQualia Announces Receipt of Milestone Payment from CJ HealthCare
Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastro esophageal Reflux Disease (GERD) at Digestive Disease Week 2018
Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD
Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastro esophageal Reflux Disease
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug ropride
Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age
Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastro esophageal Reflux Disease
Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
Jan 27, 2016: FDA Approves Takeda’s Dexilant SoluTab (dexlansoprazole)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by CJ HealthCare Corp, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Handa Pharmaceuticals LLC, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Sam-A Pharm Co Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H1 2019 (Contd..1), H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H1 2019
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H1 2019 (Contd..1), H1 2019